Editas Medicine, MGH Announce Agreement
News Aug 04, 2016
Editas Medicine, Inc. has announced that it has entered into an exclusive license agreement with Massachusetts General Hospital (MGH) to access intellectual property and technology related to high-fidelity Cas9 nucleases and Cas9 PAM variants that will enable the Company to address an expanded range of genetically-defined diseases with the potential for enhanced specificity.
“This agreement with MGH marks additional progress on our strategy of building a company committed to advancing the science behind CRISPR to benefit patients facing genetically-defined diseases,” said Katrine Bosley, President and Chief Executive Officer of Editas Medicine. “Keith Joung and his MGH team have done tremendous work in creating these novel, engineered forms of Cas9, and these advancements align fully with our highly differentiated genome editing platform. We are eager to deploy them and unlock their therapeutic potential.”
“I’m delighted to hear that MGH and Editas Medicine have entered into this important agreement,” said J. Keith Joung, M.D., Ph.D., Associate Chief for Research, the Jim and Ann Orr MGH Research Scholar in the MGH Department of Pathology, and a scientific co-founder of and consultant to Editas Medicine. “I look forward to the full potential of these high-fidelity Cas9 and Cas9 PAM variants being maximized to develop safe and effective therapies for patients with a broad range of diseases.”
As published in the January 2016 issue of Nature, MGH researchers led by Dr. Joung described their high-fidelity Cas9 variant – Streptococcus pyogenes Cas9-HF1 – designed to reduce non-specific DNA contacts. SpCas9-HF1 rendered all or nearly all off-target events undetectable by genome-wide break capture and targeted sequencing methods.
The MGH team has also identified and characterized a series of novel S. pyogenes and S. aureus Cas9 PAM variants that substantially increase the range of sites in the genome that can be targeted for genome editing. These PAM variants were described in more detail in the July 23, 2015 issue of Nature and the December 2015 issue of Nature Biotechnology. The protospacer adjacent motif, or PAM, is the region of the Cas9 protein that helps determine where Cas9 can bind to DNA.
Gene-edited Pigs are Resistant to Billion-dollar VirusNews
Scientists have produced pigs that can resist one of the world’s most costly animal diseases, by changing their genetic code. Tests with the virus – called Porcine Reproductive and Respiratory Syndrome, or PRRS – found the pigs do not become infected at all. The animals show no signs that the change in their DNA has had any other impact on their health or wellbeing.READ MORE
Gene Editing Technology May Improve Accuracy of Predicting Heart Disease RiskNews
Scientists may now be able to predict whether carrying a specific genetic variant increases a person’s risk for disease using gene editing and stem cell technologies.READ MORE
Giant Viruses Invent Their Own GenesNews
Three new members have been isolated and added to the Pandoravirus family. This strange family of viruses, with their giant genomes and many genes with no known equivalents, surprised scientists when they were discovered a few years ago. This new study notes that pandoraviruses appear to be factories for new genes – and therefore new functions.